Rev. Sep. Sci. 1(1), 47-55 (2019).
Moucun Yuan, Omnia A. Ismaiel, William R. Mylott Jr
PPD Laboratories, Richmond, VA, USA. & Department of Analytical Chemistry, Faculty of Pharmacy, Zagazig University, Egypt
Bioanalysis of protein-based therapeutics have historically used ligand binding immunoaffinity (LBA) approaches. However, recently LBA has been combined with Liquid Chromatography-Mass Spectrometry, resulting in the term hybrid (LBA)-LC-MS/MS techniques. Hybrid LC-MS/MS has successfully been applied to the bioanalysis of biotherapeutics and biomarkers. The basic concept of hybrid LC-MS/MS can be defined as combining LBA for the selective isolation/enrichment of the target analyte from the biomatrix and LC-MS for selective detection of the isolated analyte. In this article, we present a brief overview of How To develop a hybrid LBA-LC-MS/MS method for biotherapeutics and biomarkers with an emphasis on the general workflow and procedures.
KEYWORDS: Ligand Binding Immunoaffinity, Hybrid LBA-LC-MS/MS, Biotherapeutics, Biomarkers, Method Development.
Editor: Dr. Theo Noij, Charles River Laboratories, The Netherlands/Avans University of Applied Sciences, Breda, The Netherlands.
©2019 Yuan M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.